Zhaoke Ophthalmology’s TAB014 Achieves Positive Phase III Results for wAMD
China-based Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has...
HKG: 1875
Shanghai Escugen Partners with Foreseen Biotechnology for ADC Development
China-based Shanghai Escugen has entered into a partnership with domestic firm Foreseen Biotechnology to develop...
Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements
China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot...
Tot Biopharmaceutical Partners with Suzhou Smart Nuclide on Radioactive Drug Development
China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Suzhou...
Tot Biopharmaceutical Terminates Phase III Study for HER2-Targeted ADC TAA013
Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced the termination of the Phase III...
Zhaoke Ophthalmology Enrolls First Patient in TAB014 Phase III Study for wAMD
Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced the...